628 related articles for article (PubMed ID: 29300297)
1. E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.
Volz A; Jany S; Freudenstein A; Lantermann M; Ludwig H; Sutter G
Viruses; 2018 Jan; 10(1):. PubMed ID: 29300297
[TBL] [Abstract][Full Text] [Related]
2. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
[TBL] [Abstract][Full Text] [Related]
3. Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.
Volz A; Langenmayer M; Jany S; Kalinke U; Sutter G
J Virol; 2014 Sep; 88(18):10946-57. PubMed ID: 25008931
[TBL] [Abstract][Full Text] [Related]
4. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
5. Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.
Hornemann S; Harlin O; Staib C; Kisling S; Erfle V; Kaspers B; Häcker G; Sutter G
J Virol; 2003 Aug; 77(15):8394-407. PubMed ID: 12857909
[TBL] [Abstract][Full Text] [Related]
6. Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox.
Kremer M; Suezer Y; Volz A; Frenz T; Majzoub M; Hanschmann KM; Lehmann MH; Kalinke U; Sutter G
PLoS Pathog; 2012; 8(3):e1002557. PubMed ID: 22396645
[TBL] [Abstract][Full Text] [Related]
7. Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.
Perdiguero B; Gómez CE; Nájera JL; Sorzano CO; Delaloye J; González-Sanz R; Jiménez V; Roger T; Calandra T; Pantaleo G; Esteban M
PLoS One; 2012; 7(10):e48524. PubMed ID: 23119046
[TBL] [Abstract][Full Text] [Related]
8. Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.
Meseda CA; Atukorale V; Kuhn J; Schmeisser F; Weir JP
PLoS One; 2016; 11(2):e0149364. PubMed ID: 26895072
[TBL] [Abstract][Full Text] [Related]
9. Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis.
Fischer SF; Ludwig H; Holzapfel J; Kvansakul M; Chen L; Huang DC; Sutter G; Knese M; Häcker G
Cell Death Differ; 2006 Jan; 13(1):109-18. PubMed ID: 16003387
[TBL] [Abstract][Full Text] [Related]
10. Effect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model.
Meseda CA; Campbell J; Kumar A; Garcia AD; Merchlinsky M; Weir JP
PLoS One; 2013; 8(6):e67984. PubMed ID: 23785523
[TBL] [Abstract][Full Text] [Related]
11. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
[TBL] [Abstract][Full Text] [Related]
12. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
McCurdy LH; Rutigliano JA; Johnson TR; Chen M; Graham BS
J Virol; 2004 Nov; 78(22):12471-9. PubMed ID: 15507634
[TBL] [Abstract][Full Text] [Related]
13. Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection.
Knitlova J; Hajkova V; Voska L; Elsterova J; Obrova B; Melkova Z
PLoS One; 2014; 9(12):e114374. PubMed ID: 25486419
[TBL] [Abstract][Full Text] [Related]
14. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination.
Vijaysri S; Jentarra G; Heck MC; Mercer AA; McInnes CJ; Jacobs BL
Vaccine; 2008 Jan; 26(5):664-76. PubMed ID: 18096276
[TBL] [Abstract][Full Text] [Related]
15. The attenuated NYCBH vaccinia virus deleted for the immune evasion gene, E3L, completely protects mice against heterologous challenge with ectromelia virus.
Denzler KL; Schriewer J; Parker S; Werner C; Hartzler H; Hembrador E; Huynh T; Holechek S; Buller RM; Jacobs BL
Vaccine; 2011 Dec; 29(52):9691-6. PubMed ID: 21983358
[TBL] [Abstract][Full Text] [Related]
16. Identification of protective T-cell antigens for smallpox vaccines.
Ando J; Ngo MC; Ando M; Leen A; Rooney CM
Cytotherapy; 2020 Nov; 22(11):642-652. PubMed ID: 32747299
[TBL] [Abstract][Full Text] [Related]
17. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
[TBL] [Abstract][Full Text] [Related]
18. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
[TBL] [Abstract][Full Text] [Related]
20. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
Parrino J; McCurdy LH; Larkin BD; Gordon IJ; Rucker SE; Enama ME; Koup RA; Roederer M; Bailer RT; Moodie Z; Gu L; Yan L; Graham BS;
Vaccine; 2007 Feb; 25(8):1513-25. PubMed ID: 17126963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
